David Bruce Net Worth

David Bruce biography

David I. Bruce serves as President, Chief Executive Officer, Director of the Company. He most recently served as COO for Catheter Robotics, a privately held, commercial stage, remote catheter systems company. There he was responsible for planning and executing strategy for commercial market penetration, clinical studies and additional regulatory clearances for label expansion. Prior to that, Bruce served as President and CEO and Director of Arstasis, an arterial access device company, which he transitioned from development to commercialization and growth. Before Arstasis Bruce served as CEO and Director of Patient Safety Technologies, CEO and Director of EP MedSystems, and Platform General Manager of the AcuNav Catheter Business for Siemens Medical Solutions Ultrasound Division. Bruce began his career in engineering roles at Applied Materials and Optical Storage International. He holds a Master of Business Administration from the Wharton School at the University of Pennsylvania and a Bachelor of Science from the University of California, Berkeley.

What is the salary of David Bruce?

As the President, Chief Executive Officer y Director of IRIDEX, the total compensation of David Bruce at IRIDEX is $1,458,550. There are no executives at IRIDEX getting paid more.

How old is David Bruce?

David Bruce is 60, he's been the President, Chief Executive Officer y Director of IRIDEX since 2019. There are 5 older and 4 younger executives at IRIDEX. The oldest executive at IRIDEX Corp. is Robert Gunst, 72, who is the Independent Chairman of the Board.

What's David Bruce's mailing address?

David's mailing address filed with the SEC is 1212, Terra Bella Avenue, Mountain View, Santa Clara County, California, 94043, United States.

Insiders trading at IRIDEX

Over the last 21 years, insiders at IRIDEX have traded over $1,952,092 worth of IRIDEX stock and bought 1,330,571 units worth $7,196,100 . The most active insiders traders include Joshua Makower, James B Hawkins y Capital Fund, Lp Acuta. On average, IRIDEX executives and independent directors trade stock every 32 days with the average trade being worth of $18,723. The most recent stock trade was executed by Nandini Devi on 20 May 2022, trading 2,000 units of IRIX stock currently worth $6,200.

What does IRIDEX do?

iridex corporation, founded in 1989, is a worldwide leader in developing, manufacturing, and marketing innovative and versatile light-based medical systems and delivery devices. we offer laser based solutions for multiple specialties including aesthetic medicine, ophthalmology, and otolaryngology. we also maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. with superior technology for superior results, iridex is dedicated to standards of excellence that meet your own.

IRIDEX executives and stock owners

IRIDEX executives and other stock owners filed with the SEC include:

• David Bruce,
  President, Chief Executive Officer, Director
• Fuad Ahmad,
  Interim Chief Financial Officer
• Patrick Mercer,
  Chief Operating Officer
• David I. Bruce,
  Pres, CEO & Director
• Patrick Mercer,
  Chief Operating Officer
• Fuad Ahmad,
  Interim Chief Financial Officer
• Doris Engibous,
  Independent Director
• Lynn Lewis,
  IR Contact Officer
• Robert Gunst,
  Independent Chairman of the Board
• Scott Shuda,
  Independent Director
• Kenneth Ludlum,
  Independent Director
• Robert Grove,
  Independent Director
• Leigh Salvo,
  Head of Investor Relations
• George R Marcellino,
  Director
• Capital Partners, L.P.Blue ...,
  
• Ruediger Naumann Etienne,
  Director
• Romeo R Dizon,
  
• Sanford Fitch,
  Director
• Atabak Mokari,
  CFO and VP Corp Development
• Ronald Steckel,
  VP, Operations
• Capital Partners, L.P.Blue ...,
  
• Associates & Paragon Associ...,
  
• William M Moore,
  Director
• James H Mackaness,
  Chief Financial Officer
• Barry G Caldwell,
  President and CEO
• Larry Tannenbaum,
  Chief Financial Officer
• James L Donovan,
  VP, Corporate Business Develp.
• Beverly A Huss,
  Director
• Ann D Rhoads,
  Director
• Maria Sainz,
  Director
• Ken Ludlum,
  Director
• Capital Fund, Lp Acuta,
  10% owner
• John M Nehra,
  Director
• Joshua Makower,
  Director
• Nandini Devi,
  Director
• Capital Partners, L.P.Blue ...,
  
• Catalyst Fund Ix, L.P.Blue ...,
  
• Catalyst Fund Ix, L.P.Blue ...,
  
• James B Hawkins,
  Director
• Garrett A Garrettson,
  Director
• Catalyst Fund Ix, L.P.Blue ...,
  
• Eduardo Arias,
  Sr. VP, Int'l Sales & Bus...
• Robert K Anderson,
  Director
• Partners, L.L.C.Blue Line P...,
  
• Dominik Beck,
  President and CEO
• Partners, L.L.C.Blue Line C...,
  
• Donald J Todd,
  VP Marketing
• Capital Partners Ii, L.P.Bl...,
  
• Partners, L.L.C.Blue Line C...,
  
• Theodore A Boutacoff,
  President and CEO
• Timothy S Powers,
  Vice President, Operations
• Partners, L.L.C.Blue Line C...,
  
• Partners, L.L.C.Blue Line P...,
  
• Donald L Hammond,
  Director
• Partners, L.L.C.Blue Line C...,
  
• Partners, L.L.C.Blue Line C...,